Results 51 to 60 of about 247,670 (219)

Consequences of the recurrent MYD88 L265P somatic mutation for B cell tolerance [PDF]

, 2014
MYD88L265P has recently been discovered as an extraordinarily frequent somatic mutation in benign monoclonal IgM gammopathy, Waldenström's macroglobulinemia, and diffuse large B cell lymphoma.
Beutler, Bruce, Goodnow, Christopher, Horikawa, Keisuke, Jeelall, Yogeshraj, Wang, James   +4 more
core   +1 more source

Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas

Haematologica, 2008
Background Follicular lymphomas are currently subdivided into grades I, II, IIIa and IIIb. This distinction is, however, questioned.Design and Methods We studied the gene expression profile of 43 follicular lymphomas, 50 B-cell non-Hodgkin’s lymphomas of
Pier Paolo Piccaluga, Andrea Califano, Ulf Klein, Claudio Agostinelli, Beatriz Bellosillo, Eva Gimeno, Sergi Serrano, Francisco Solè, Yonghui Zang, Brunangelo Falini, Pier Luigi Zinzani, Stefano A. Pileri   +11 more
doaj   +1 more source

Diffuse large B-cell lymphoma with uncommon cardiac invasion

SAGE Open Medical Case Reports, 2022
Diffuse large B-cell lymphoma is the most common histologic subtype of non-Hodgkin lymphoma. Secondary involvement of the heart is seen late in advanced cases, it is uncommon for diffuse large B-cell lymphoma to present as intracardiac mass.
Yunis Daralammouri, Hamza Hamayel, Yahya Ismail, Sajed Majadla, Razan Odeh   +4 more
doaj   +1 more source

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology, 2019
PURPOSE Patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) fare poorly, with limited treatment options.
L. Sehn, A. Herrera, C. Flowers, M. Kamdar, A. McMillan, M. Hertzberg, S. Assouline, T. Kim, W. Kim, M. Ozcan, J. Hirata, E. Penuel, J. Paulson, J. Cheng, G. Ku, M. Matasar   +15 more
semanticscholar   +1 more source

Spinal cord compression by B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a patient seropositive for human immunodeficiency virus: a case report [PDF]

, 2014
INTRODUCTION: Although non-Hodgkin’s lymphoma is one of the most common and frequently fatal of the acquired immune deficiency syndrome-defining illnesses, survival has improved significantly since the introduction of antiretroviral therapy.
Jun-Yeong Seo, Kee-Yong Ha, Min-Up Kim, Yoon-Chung Kim, Young-Hoon Kim   +4 more
core   +1 more source

Глобализация как фактор радикализации трансформации приоритетов социально-экономического развития в посттранзитивних экономиках [PDF]

, 2011
Expression of the for khead transcription factor FOXP1 is essential for early B-cell development, whereas down regulation ofFOXP1at the germinal center (GC) stage is required for GC B-cell function. Aberrantly high FOXP1 expression is frequently observed
Banham, Basso, Bende, Bende, Berkowska, Berkowska, Ding, Dogan, Engels, Fenton, Fornek, Goldstein, Gutiérrez, Hans, Horikawa, Hu, Iida, Iqbal, Klein, Kocemba, Kometani, Kuo, Kwon, Lenz, Lenz, Leonie J. Grüneberg, Lin, Liu, Mandelbaum, Marcel Spaargaren, Martin, Martine van Keimpema, McHeyzer-Williams, Menno C. van Zelm, Michal Mokry, Nera, Nutt, Ochiai, Pape, Paul Coffer, Rampanelli, Ruben van Boxtel, Rui, Sagaert, Sagardoy, Scheeren, Schmidlin, Sciammas, Seifert, Shaffer, Shaffer, Shaffer, Shaffer, Shapiro-Shelef, Staudt, Steven T. Pals, Streubel, Taylor, Tunyaplin, van Boxtel, van Keimpema, Vegliante, Yoshida, Zuccarino-Catania   +63 more
core   +2 more sources

Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma

Haematologica, 2012
Background FoxM1 has been shown to play a critical role in the pathogenesis of various epithelial malignancies. However, its role in lymphoid malignancies has not been fully clarified.
Shahab Uddin, Azhar R Hussain, Maqbool Ahmed, Khawar Siddiqui, Fouad Al-Dayel, Prashant Bavi, Khawla S. Al-Kuraya   +6 more
doaj   +1 more source

Derepressing of STAT3 and USP7 contributes to resistance of DLBCL to EZH2 inhibition

Heliyon, 2023
Diffuse large B-cell lymphoma is the most common subtype of lymphoma, representing ∼25 % of non-Hodgkin lymphoid malignancies. EZH2 is highly expressed in Diffuse large B-cell lymphoma and ∼22 % of patients contain EZH2 mutations.
Chenyun He, Wenbin Zhou, Xiaoxia Jin, Haining Zhou   +3 more
doaj   +1 more source

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

Blood Cancer Journal, 2020
CD19-targeted chimeric antigen receptor (CAR) T cell therapy is an effective treatment for diffuse large B cell lymphoma (DLBCL). In addition to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS), B cell aplasia and
K. Wudhikarn, M. Palomba, M. Pennisi, M. García‐Recio, Jessica R. Flynn, S. Devlin, A. Afuye, M. Silverberg, M. Maloy, G. Shah, M. Scordo, P. Dahi, C. Sauter, C. Batlevi, B. Santomasso, E. Mead, Susan K. Seo, M. Perales   +17 more
semanticscholar   +1 more source

The small FOXP1 isoform predominantly expressed in activated B cell-like diffuse large B-cell lymphoma and full-length FOXP1 exert similar oncogenic and transcriptional activity in human B cells

Haematologica, 2017
The forkhead transcription factor FOXP1 is generally regarded as an oncogene in activated B cell-like diffuse large B-cell lymphoma. Previous studies have suggested that a small isoform of FOXP1 rather than full-length FOXP1, may possess this oncogenic ...
Martine van Keimpema, Leonie J. Grüneberg, Esther J.M. Schilder-Tol, Monique E.C.M. Oud, Esther A. Beuling, Paul J. Hensbergen, Johann de Jong, Steven T. Pals, Marcel Spaargaren   +8 more
doaj   +1 more source